Preclinical Validation of Behavioral, Molecular, and Electrophysiological Effects of Acamprosate in a Mouse Model of Angelman Syndrome

$81,631

The principal objective of these studies is to determine if acamprosate, a drug that is approved by the Food and Drug Administration for the treatment of alcoholism in adults and works to correct imbalances in excitatory and inhibitory signaling in the brain, is a viable treatment option in Angelman syndrome (AS).  Acamprosate will be rigorously tested in the AS mouse for improved brain signaling, as well as in several behavioral tests for learning, memory and motor functioning compared to typical mice.  Validation in the mouse model may lead to expedited clinical trials in individuals with AS.